Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?

Immunophenotypic changes are not rare after neoadjuvant chemotherapy for breast cancer. Several recent publications addressing this issue have suggested that the discordance between pre-chemotherapy and post-chemotherapy estrogen receptors, progesterone receptors, and HER2 is around 10%, 20%, and 10...